NCT03777124

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer

Conditions

• NSCLC Stage IV
• KRAS Gene Mutation
• PD-1 Antibody
• Chemotherapy Effect

Interventions

Type	Name	Description
DRUG	SHR-1210	Subjects receive SHR-1210 intravenous every 2 weeks
DRUG	Apatinib	Subjects receive Apatinib orally every day
DRUG	Pemetrexed	Subjects receive Pemetrexed intravenous every 3 weeks
DRUG	Carboplatin	subjects receive carboplatin intravenous every 3 weeks

Timeline

• Start date: 2019-07-11
• Primary completion: 2023-06-29
• Completion: 2023-06-29
• First posted: 2018-12-17
• Last updated: 2025-07-04

Locations

1 site across 1 country: China